Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir by Robertson, K. et al.
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected
participants randomized to continue tenofovir/emtricitabine
+ atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
Kevin Robertson1 & Paul Maruff2 & Lisa L. Ross3 & David Wohl4 & Catherine B Small5,6 & Howard Edelstein7 &
Mark S. Shaefer3
Received: 19 April 2018 /Revised: 6 September 2018 /Accepted: 12 September 2018 /Published online: 8 October 2018
# The Author(s) 2018
Abstract
Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite
achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was
evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory
in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized par-
ticipants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to
abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically
adjusted normative data and were classified as Bimpaired^ (defined as either a z-score ≤ − 2 or having 2 or more
standardized individual test z-scores ≤ − 1); while higher scores (equaling better performance) were classified as
Bnormal^. By z-scores, 54.7% of participants had impaired neurocognition at baseline and 50.2% at week 48.
There were no significant differences (p < 0.05) in the baseline-adjusted performance between treatment groups for
any individual test or by z-score. Specific demographic and medical risk factors were evaluated by univariate
analysis for impact on neurocognitive performance. Factors with p < 0.10 were evaluated by backwards regression
analysis to identify neurocognition-correlated factors after accounting for treatment, assessment, and baseline. Four
risk factors at baseline for impaired neurocognition were initially identified: lower CD4 nadir lymphocyte counts,
higher Framingham risk scores, and interleukin-6 levels, and a history of psychiatric disorder not otherwise specified,
however none were found to moderate the effect of treatment on neurocognition. In this aviremic, treatment-
experienced population, baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks
with both TDF/FTC + ATV/r-treated and in the ART-simplified ABC/3TC + ATV treatment groups.
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Introduction
The use of ART in patients infected with HIV-1 has greatly in-
creased survival and decreased the incidence of HIV-1 andAIDS-
associated conditions, such as Kaposi’s sarcoma, Pneumocystis
jirovecii pneumonia, and HIV-associated dementia. However,
milder HIV-associated neurological disorders (HAND) have been
noted in patients on ART, including those with suppressed viral
loads. (Zhou and Saksena 2013; Simioni et al. 2010; Heaton et al.
2010; Saylor et al. 2016). Less is known about how the choice of
ART impacts the likelihood of HAND in aviremic patients.
Simplification studies provide a unique opportunity to investigate
this issue, particularly given that current treatment guidelines, such
as those from the US Department of Health and Human Services
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(DHHS) have endorsed regimen simplification for reducing pill
burden, enhancing tolerability, improving quality of life, and de-
creasing the risk of some long-term toxicities (DHHS Panel on
Antiretroviral Guidelines for Adults and Adolescents 2018). One
simplification strategy is the discontinuation of low-dose ritonavir
in aviremic patients, an approach that has been found to maintain
virologic suppression, decrease the incidence of ritonavir-
associated adverse events, and potentially reduce the incidence
of CYP3A-mediated drug interactions (DHHS Panel on
Antiretroviral Guidelines for Adults and Adolescents 2018;
Elion et al. 2010; Gatell et al. 2007; Ghosn et al. 2010; Pavie
et al. 2011; Santos et al. 2009; Sension et al. 2009; Soriano
et al. 2008; Squires et al. 2010).
The randomized, open-label ASSURE (A Simplification
Study of Unboosted Reyataz with Epzicom) study investigat-
ed the efficacy and safety of discontinuing ritonavir in viro-
logically suppressed participants currently receiving a regi-
men of TDF/FTC plus ATV/r. Study participants were ran-
domized to continue that regimen or to discontinue ritonavir
while simultaneously switching to a fixed-dose combination
(FDC) of the nucleoside reverse transcriptase inhibitors
(NRTIs) abacavir and lamivudine ABC/3TC. The previously
published 24- and 48-week efficacy results demonstrated that
there was no significant difference between the two treatment
groups by a time to loss of virologic response (TLOVR) anal-
ysis (Wohl et al. 2014; Wohl et al. 2016). To assist with un-
derstanding how the choice of ART may impact HAND in
aviremic patients, one exploratory aim of the ASSURE study
was to examine how simplification to ABC/3TC + ATV af-
fected neurocognition through the 48 weeks of the study.
Methods
Clinical study description
Briefly, ASSURE (EPZ113734; NCT01102972) was a pro-
spective, randomized, multicenter, open-label, and phase IV
study that enrolled HIV-1-infected, ART-experienced adults
(≥ 18 years of age) who had received a once-daily regimen
of TDF/FTC 300 mg/200 mg (Gilead Sciences, Foster City,
CA, USA) + ATV 300 mg (Bristol-Myers Squibb, Princeton,
NJ, USA) boosted with ritonavir 100 mg (AbbVie, Chicago,
IL, USA) for ≥6 months and had HIV-1 RNA ≤ 75 copies/mL
for at least 28 days prior to the screening visit. As part of the
inclusion and exclusion criteria, participants were excluded if
they were HLA-B*5701-positive or had prior abacavir expo-
sure, active CDC clinical category C disease, ongoing clini-
cally relevant hepatitis and/or chronic hepatitis B infection
(HBsAg+), or a creatinine clearance < 50 mL/min via the
Cockroft-Gault method. Additional information regarding all
inclusion/exclusion criteria, methods, and endpoints, includ-
ing a link to the protocol, is available in the 24-week efficacy
results publication (Wohl et al. 2014). All participants provid-
ed written informed consent to participate in the study, and the
protocol was approved by the institutional review board for
each study site.
After stratification by prior ART experience (TDF/FTC +
ATV/r as the initial regimen or as the first/s switch regimen),
eligible participants were randomized 2:1 to simplify their
regimen to once-daily ABC/3TC 600 mg/300 mg (ViiV
Healthcare, Research Triangle Park, NC, USA) plus ATV
600 mg or remain on TDF/FTC + ATV/r. The ASSURE study
was powered to evaluate its primary endpoint, which was the
proportion of participants with HIV-1 RNA < 50 copies/mL at
week 24 by the time to loss of virologic failure (TLOVR)
algorithm. Eighty-seven percent of participants in both treat-
ment groups successfully maintained HIV-1 RNA < 50
copies/mL at week 24, demonstrating non-inferiority of sim-
plification to ABC/3TC + ATV compared with continuation
of TDF/FTC + ATV/r (Wohl et al. 2014). Results at week 48
were similar, with HIV-1 RNA < 50 copies/mL in 76% of
participants taking ABC/3TC + ATVand 79% of participants
taking TDF/FTC + ATV/r (Wohl et al. 2016).
Neurocognitive assessments
Neurocognition was measured in the ASSURE study with a
computerized cognitive test battery, the Cogstate Brief Battery
(CBB; Cogstate; Melbourne, Australia). The CBB was select-
ed because of its demonstrated sensitivity to HIV-related CNS
impairment, (Maruff et al. 2009; Bloch et al. 2016) sensitivity
to the effects of CNS active drugs generally (e.g., Grove et al.
2014; McIntrye et al. 2014), and to the effects of ART with
CNS penetration (Winston et al. 2015). The CBB includes
four cognitive tests which assess psychomotor function, atten-
tion, learning, and working memory which have previously
been described in detail (Cysique et al. 2006). The CBB re-
quires approximately 15 min for completion in HIV-infected
adults; a single performance measure is generated for each of
these four tests. Analyses of the neurocognitive data were
conducted on the intent-to-treat exposed (ITT-E) population.
All participants completed the entire CBB at a pre-baseline
familiarization assessment, a baseline assessment and then an
assessment at the week 24, week 48, and if an early withdraw-
al from the study occurred. Data from the familiarization visit
was not used in the analyses.
To provide a measure of global neurocognition, a z-score
was derived from the four tests in the CBB for each participant
at each assessment. Each time, a study participant completed
the CBB; their data were uploaded to a secure database and
processed to provide the four primary outcome measures.
Each outcome measure was then standardized using
demographic-adjusted normative data and summed to com-
pute a z-score, which was a neuropsychological composite
of the four tests that was used to define global neurocognition.
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For each assessment, each participant’s neurocognition was
categorized as either Bimpaired^ (defined as either a z-score ≤
− 2 or having two or more standardized individual test z-
scores ≤ − 1), while higher scores (equating to better perfor-
mance) were classified as Bnormal.^ The normative dataset
used as a comparator in this analysis was obtained by
Cogstate from a healthy, non-HIV-infected population. The
normative dataset used in this analysis was stratified by age
group, and was similar in composition to the ASSURE study
participants in terms of age and gender distributions and
where possible, was of similar ethnicity; as previously been
described (Haddow et al. 2017).
Statistical analysis
The primary exploratory analysis objective was to determine
the extent to which 24 and 48 weeks of treatment with ATV +
ABC/3TC versus ATV/r + TDF/FTC was associated with
changes in neurocognition in the ITT-E population. Study
participants must have attempted the baseline and either one
or both of the week 24 and week 48 assessments to be includ-
ed in analyses of neurocognition. Data were analyzed using a
series of linear mixed models in which the baseline was
modeled as a covariate and treatment group (ABC/3TC +
ATV and TDF/FTC + ATV/r) and assessment were modeled
as fixed factors. The z-scores, as well as the scores from each
of the CBB tests, were modeled separately as the dependent
variable. Any early withdrawal or unscheduled visit assess-
ment done between week 12 and week 35was reclassified into
the week 24 assessment group; any assessment performed at
week 36 or beyond was classified as week 48 assessments.
Through week 48, results for the two treatment groups were
compared using an analysis of covariance (ANCOVA) adjust-
ed for baseline performance scores. Cohen’s d was calculated
to estimate the magnitude of the differences between the two
treatment groups; effect sizes of 0.2–0.4 are considered mild,
0.5–0.7 considered moderate, and ≥ 0.8 considered large
(Cohen 1988). To validate the model assumption that the re-
lationship between baseline and outcome were parallel for
each treatment group, a baseline by treatment interaction
was included in the model and removed only if the corre-
sponding p value was > 0.05. A secondary analysis was also
conducted to determine the extent to which 24 and 48 weeks
of treatment with ATV +ABC/3TC versus ATV/r + TDF/FTC
was associated with changes in neurocognition but restricted
to the population of study participants with virologic suppres-
sion. The analysis population included participants with z-
scores at the 24 or 48 week assessment visits and who had
HIV-1 RNA < 50 copies/mL, as assessed by the time to loss of
virologic response (TLOVR) algorithm, and the analysis com-
pared the measures of cognition by treatment group and the
effect sizes for treatment differences.
In another secondary analysis, the potential association be-
tween selected covariate risk factors (body mass index, CD4
nadir lymphocyte count, high-sensitivity C-reactive protein, de-
pression, type I diabetes, type II diabetes, Framingham 10-year
coronary heart disease risk score, interleukin 6 level, psychiatric
disorders not otherwise specified, study stratification, the total
weighted CNS penetration effectiveness (TWCPE) score), and
neurocognitive performance (impaired versus normal) were ex-
amined using a two-tiered approach. First, a univariate analysis
was conducted on each of the factors to determine their relation-
ship to neurocognitive performance. Factors classified as differ-
ent (i.e., p value < 0.10) were then submitted to a backwards
regression process to identify those that correlatedmost strongly
with neurocognition, after accounting for all the other relevant
exploratory factors. The first stage, the univariate analyses, was
conducted to identify the variables to be used in the backwards
regression. This method was employed to avoid an over-
saturated model at the start of the backwards regression process.
The effect of the demographic and medical covariates on per-
formance on the Cogstate battery was further investigated by
determining which factors were associated with a change in
performance over time for each Cogstate test. All data analyses
were conducted using Statistical Analytic Software (SAS v9.2;
Cary, North Carolina, United States).
Results
Almost all (293/296; 99%) of the ASSURE study participants
were included after having provided valid and complete base-
line data for one or more of the four CBB tests. By the same
criterion, 92% (272/296) of study participants completed an
assessment at week 24 and 81% (240/96) at week 48.
All data received was submitted to test completion and data
integrity checks (performed by Cogstate) to ensure that the
data reflected performance on the test and that the demands
of the test were understood. The analysis showed that the test
battery was well tolerated in this study population; 99.67% of
data were analyzed with ten test completion failures. After
data cleaning, a total of 1089 tests were received across the
pre-baseline, baseline, week 24, week 48, early withdrawal,
and unscheduled visit assessments. The pre-specified data in-
tegrity checks were passed by 94.3% of the data at the analysis
points (baseline, week 24, week 48, or withdrawal visits).
Based on the high proportion of scores that met the integrity
criteria, the entire data set was included in the ITT-E analysis.
Study population
The enrolled participants were predominantly male and white
(Table 1), although more than a third were African-American.
All participants were from sites in the USA and Puerto Rico.
More than 25% of participants identified as Hispanic or Latino.
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At baseline, nearly half of the participants had taken ≥ 1 ART
regimen before starting TDF/FTC + ATV/r, and the median
time on ART was approximately 3 years. The mean z-scores
calculated at the baseline assessment for each of the two treat-
ment groups were not significantly different, with a mean of −
1.155 (standard deviation 1.087; n = 180) for the ABC/3TC +
ATV treatment group and a mean of − 1.1755 (standard devi-
ation 1.136, n = 83) for the TDF/FTC +ATV/r treatment group.
At the start of the ASSURE study, 54.7% of the ART-
experienced study participants were assessed as having im-
paired neurocognition (Table 2) and 50% or more of all par-
ticipants were classified as having impaired neurocognition in
the post-baseline assessments. While the overall proportions
remained similar, the neurocognitive assessments for an indi-
vidual participant did not always remain static. In an evalua-
tion of the change from baseline (CFB) results at the week 24
assessment, approximately 25% of participant assessments
had a change from their baseline classification status (from
normal to impaired or from impaired to normal). Overall, a
small proportion (13.3%) of participants went from a classifi-
cation of impaired at baseline to normal at week 48, while a
smaller proportion (8.7%) saw a change from normal to im-
paired neurocognition. Overall, at week 48, 50% of partici-
pants were classified as normal, while 50% were classified as
impaired, similar to the proportions observed for the study
population at baseline.
The results for each of the individual tests and the z-scores
were obtained for study participants with evaluable data and
tabulated by treatment group (Table 3). There were no signif-
icant differences in the baseline-adjusted performance be-
tween the participants taking ABC/3TC + ATVand those tak-
ing TDF/FTC + ATV/r for any individual neurocognitive test
or for the composite z-score. Consideration of the effect sizes
indicated the magnitude for these group differences was uni-
formly small (i.e., d < 0.2).
As not all participants remained virologically suppressed
through 48 weeks in either treatment group, a secondary anal-
ysis assessed whether there was any differential impact by
treatment group on neurocognition, as assessed by the z-scores,
for those participants who maintained virologic suppression
(HIV-RNA < 50 copies/mL) through 24 or 48 weeks. By treat-
ment group, for the comparison of ATV + ABC/3TC to ATV/r
+ TDF/FTC, there were 143 and 73 participants, respectively at
week 24 who had remained virologically suppressed and had
neurocognitive test results at baseline and week 24 and 142
and 70 virologically suppressed participants, respectively at
week 48 with z-scores at baseline and week 48. The adjusted
mean difference and 95% upper and lower CI for the compar-
ison at weeks 24 and 48 were − 0.195 (− 0.435; 0.045) and
0.097 (− 0.332; 0.137), respectively. Cohen’s d effect size at
weeks 24 and 48 were − 0.230 and − 0.120, and the p values
were 0.111 and 0.414, respectively. Similar results were ob-
served for analyses performed for each of the individual tests
within the test battery and for all measures of neurocognition,
the effect sizes for treatment differences remained small in
magnitude and none were statistically significant.
Covariate analyses
Analysis of the demographic and medical factors associated
with a classification of impaired neurocognitive performance
at the baseline assessment was performed to explore whether
specific demographic or illness-related variables could mod-
erate the effect of treatment. For the detection test, while the
regression analyses identified high-sensitivity C-reactive pro-
tein as a covariate of interest, it no longer had any significance
on the relationship between treatment and neurocognition af-
ter the backwards regression was conducted. For the identifi-
cation test, the covariates psychiatric disorder not otherwise
specified and CD4 nadir lymphocyte cell counts were found to
be significant at the alpha level of 0.1 and remained in the
model after baseline, treatment and visit were added. After
adjusting for psychiatric disorder not otherwise specified and
CD4 nadir lymphocyte count, the effect of treatment on
neurocognition was similar (p value = 0.234 vs. p value =
0.178). For the one card-learning test, psychiatric disorder
not otherwise specified, type II diabetes, stratification, and





ATV/r (N = 97)
Median age, years (range) 44 (21–66) 42 (20–68)




122 (61) 55 (57)
African American/African her-
itage
65 (33) 37 (38)
Other 12 (6) 5 (5)
Hispanic or Latino ethnicity,
n (%)
51 (26) 26 (27)
Median plasma HIV-1 RNA,
log10 copies/mL
1.59 1.59
< 50 copies/mL, n (%) 192 (96) 93 (96)
Median CD4+ cell count,
cells/mm (range)
492 (77–1196) 480 (108–1479)
< 200 cells/mm, n (%) 14 (7) 6 (6)
CDC Class C HIV infection,
n (%)
37 (19) 17 (18)
Hepatitis C coinfection, n (%) 18 (9) 8 (8)
Median time on prior ART,
days (range)
978 (177–4830) 1106 (199–7078)
≥ 1 prior regimen before starting
TDF/FTC + ATV
43% 43%
ABC/3TC, abacavir/lamivudine; ART, antiretroviral therapy; ATV,
atazanavir; ATV/r, atazanavir/ritonavir; CDC, Centers for Disease
Control and Prevention; TDF/FTC, tenofovir/emtricitabine
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depression were significant after the univariate regression,
however none of these covariates remained significant after
the backwards regression process. For the one back test, de-
pression was significant in the univariate analysis and
remained in the model when treatment, baseline and visit were
controlled. However, after adjusting for the effect of depres-
sion history on neurocognitive performance, the effect of
treatment on neurocognition was similar (p value = 0.340 vs.
p value = 0.571). None of the covariates were significant in
the univariate analysis for the z-score (all p values > 0.1).
When performance on the neurocognitive tests at baseline
was considered categorically as being impaired or normal
(Table 4), differences were found for four factors: lower
CD4 lymphocyte count at nadir, higher scores on the
Framingham risk factor and higher values for interleukin 6,
and having a history of psychiatric disorder not otherwise
specified. For the continuous variables (Framingham risk,
CD4 nadir lymphocyte count, and interleukin 6), the magni-
tude of differences in covariate score between impaired and
normal neurocognition was expressed using Cohen’s d. For
Table 2 Percentage of study participants classified as having either impaired or normal neurocognition at each assessment
Assessment Classification N* % of total
Baseline Normal neurocognition 120 45.3
Baseline Impaired neurocognition 145 54.7
Week 24 Normal neurocognition 122 47.1
Week 24 Impaired neurocognition 137 52.9
Week 48 Normal neurocognition 120 49.8
Week 48 Impaired neurocognition 121 50.2
CFB to week 24 Change from normal to impaired neurocognition at week 24 29 11.2
CFB to week 24 Change from impaired to normal neurocognition at week 24 36 13.9
CFB to week 24 No change at week 24—impaired neurocognition 108 41.7
CFB to week 24 No change at week 24—normal neurocognition 86 33.2
CFB to week 48 Change from normal to impaired neurocognition at week 48 21 8.7
CFB to week 48 Change from impaired to normal neurocognition at week 48 32 13.3
CFB to week 48 No change at week 48—impaired neurocognition 100 41.5
CFB to week 48 No change at week 48—normal neurocognition 88 36.5
CFB, change from baseline
*This table count does not include 30 study participants who were missing a classification due to missing data on at least one of their assessments
Table 3 Overall comparison of ATV + ABC/3TC to ATV/r + TDF/FTC treatment groups at weeks 24 and 48 using the adjusted means from the linear
mixed model analysis for each of the individual tests and the composite z-score for the intent to treat-exposed population
Test Population Week 48 adjusted mean difference (95% CI) Cohen’s d effect size p value
ABC/3TC+ ATV, n TDF/FTC+ ATV/r, n
Week 24
Detectiona 172 82 0.004 (− 0.026, 0.033) 0.032 0.811
Identificationa 172 83 0.015 (− 0.006, 0.036) 0.183 0.172
Once card learningb 175 84 − 0.006 (− 0.030, 0.018) − 0.062 0.639
One back memorya 174 84 0.012 (− 0.012, 0.036) 0.134 0.316
z-scoreb 172 83 − 0.128 (− 0.39, 0.094) − 0.152 0.257
Week 48
Detectiona 156 75 0.006 (− 0.026, 0.037) 0.050 0.721
Identificationa 142 70 0.011 (− 0.010, 0.032) 0.147 0.291
Once card learningb 145 70 0.003 (− 0.027, 0.032) 0.024 0.865
One back memorya 144 70 − 0.001 (− 0.026, 0.023) − 0.013 0.923
z-scoreb 142 70 − 0.054 (− 0.281, 0.172) − 0.066 0.638
ABC/3TC, abacavir/lamivudine; ATV, atazanavir; ATV/r, atazanavir/ritonavir; CI, confidence interval; TDF/FTC, tenofovir/emtricitabine
a A negative difference score and negative effect size indicate that ATV + ABC/3TC performance was improved over ATV/r + TDF/FTC
bA positive difference score and positive effect size indicate that ATV + ABC/3TC performance was improved over ATV/r + TDF/FTC
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Table 4 Risk factors by participants classified as either normal or impaired neurocognition at the baseline assessment







Body mass index Normal 28.559 7.198
Body mass index Impaired 28.419 6.065 − 0.140 − 0.021 0.706
CD4 nadir Normal 320.214 226.5
CD4 nadir Impaired 289.172 192.8 − 31.042 − 0.148 0.011
High-sensitivity C-reactive protein Normal 3.957 9.735
High-sensitivity C-reactive protein Impaired 3.392 5.894 − 0.564 − 0.072 0.214
Depression (current) Normal 0.094 0.191
Depression (past) Normal 0.049
Depression (not assessed) Normal 0.004
Depression (no medical condition) Normal 0.306
Depression (current) Impaired 0.166 1.718 (0.96, 3.06)
Depression (past) Impaired 0.068 1.351 (0.62, 2.94)
Depression (no medical condition) Impaired 0.313
Diabetes type II (current) Normal 0.026 0.274
Diabetes type II (past) Normal 0.008
Diabetes type II (no medical condition) Normal 0.419
Diabetes type II (current) Impaired 0.026 0.804 (0.27, 2.36)
Diabetes type II (no medical condition) Impaired 0.521
Framingham scored Normal 3.161 4.152
Framingham scored Impaired 3.757 5.525 0.597 0.120 0.030
Interleukin 6 Normal 2.452 3.350
Interleukin 6 Impaired 3.517 5.748 1.065 0.222 0.000
Psychiatric disorderse (current) Normal 0.094 0.030
Psychiatric disorderse (past) Normal 0.004
Psychiatric disorderse (not assessed) Normal 0.004
Psychiatric disorderse (no medical condition) Normal 0.351
Psychiatric disorderse (current) Impaired 0.102 0.948 (0.51, 1.75)
Psychiatric disorderse (past) Impaired 0.045 10.528 (1.34, 82.51)
Psychiatric disorderse (no medical condition) Impaired 0.400
Stratification (initial antiretroviral regimen:
ATV/r + TDF/FTC)
Normal 0.294 0.657
Stratification (initial antiretroviral regimen:
NNRTI + TDF/FTC)
Normal 0.158 0.657
Stratification (initial antiretroviral regimen:
ATV/r + TDF/FTC)
Impaired 0.370
Stratification (initial antiretroviral regimen:
NNRTI + TDF/FTC)
Impaired 0.177 1.123 (0.67, 1.87) 0.657
TWCPEf Normal 6.129 0.693
TWCPEf Impaired 6.091 0.420 − 0.038 − 0.067 0.281
a Rather than mean, the proportion, where relevant, was calculated
b The magnitude of difference was calculated either by Cohen’s d or odds ratio for odds of impaired neurocognition; for the odds ratio, these were
calculated as the odds of impaired neurocognitive performance with regard to a reference category. For depression, psychiatric disorders and diabetes
type 2, the reference category is Bno medical condition.^ For stratification, the reference category is BInitial antiretroviral regimen: ATV/r + TDF/FTC.^
Where there is not enough data in the relevant category, odds ratios are not calculated. The 95% confidence intervals for the odds ratios are also given
c p values were calculated by Student’s t test or by chi-squared for categorical variables (H0:no difference in means)
d 10-year coronary heart disease Framingham risk score
e This variable encompassed all psychiatric disorders not otherwise specified
f Total weighted cerebrospinal fluid penetration effectiveness score
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the categorical variable history of psychiatric disorder, the
effect was expressed by computing the odds of impaired
neurocognition with a history of psychiatric disorder com-
pared to no medical condition. The magnitudes of differences
in covariates for Framingham risk, CD4 nadir lymphocyte
count, and interleukin 6 covariates were small (d < 0.2).
However, a history of psychiatric disorder increased the odds
of current classification of impaired neurocognition tenfold.
The effect of the demographic and medical covariates on
performance for the CBBwas further investigated by determin-
ing which factors were associated with change in performance
over time for each Cogstate test. Any significant factors that
were identified were added to a backwards regression model
with that included terms for the baseline, assessment, and for
treatment. Demographic and medical covariates were consid-
ered to have influenced performance if the relationship with
change in performance remained statistically significant in the
backwards regression model. These analyses identified no co-
variate that influenced a change in performance on the detec-
tion test, one card-learning test, or the z-score neurocognitive
measurements. For the identification test, a history of psychi-
atric disorder not otherwise specified and CD4 nadir lympho-
cyte count was associated with cognitive performance after
taking into account the baseline, assessment, and treatment
effects. For the one back test, a history of depression was asso-
ciated with cognitive performance after taking into account the
baseline assessment as well as treatment effects. In both cases,
the study treatments had no effect on neurocognition.
Taken together, these analyses indicate that after adjusting
for baseline and relevant demographic and medical covariates
there were no differences in performance between the ATV +
ABC/3TC and ATV/r + TDF/FTC treatment arms for any of
the Cogstate outcomes. While these risk factors were identi-
fied to be associated with neurocognitive performance over all
assessments (baseline, week 24 or 48), none of these risk
factors were found to moderate the effect of treatment on
neurocognition.
Discussion
The analysis of the assessment data indicated that the
neurocognitive test battery was well tolerated in the USA/
Puerto Rican study population and that performance on the
battery was in accord with requirements, based on the very
low rates of missing data and failure of data integrity across all
study treatments and assessments. The estimates of within par-
ticipant variability in performance were also consistent with
those observed in previous studies of healthy adults performing
the same Cogstate test battery. With levels of neurocognition
taken into account, we observed no difference between the
ATV + ABC/3TC and ATV/r + TDF/FTC treatment groups in
psychomotor function, attention, working memory, or memory
and also for a composite measure of these (z-score) which pro-
vided an index of general neurocognition. These results demon-
strated that in this population, participants in the ATV + ABC/
3TC treatment groupwere able to reduce their overall number of
prescribed ARTmedications and simplify to an unboosted ART
regimenwith no negative impact on neurocognition. In all cases,
the magnitude of the differences between treatment groups in
baseline-adjusted group mean performance at the 48-week as-
sessment were, by convention, trivial (i.e., effect sizes less than
0.2). Hence, when considered with the large sample size, these
very small group differences suggest strongly the absence of any
statistical significance or treatment terms in the analysis
reflected that groups were truly not different, as opposed to
arising from any low statistical power. Similarly, a secondary
analysis evaluated the effect of the treatment simplification at
the 24 and 48 week time points for those participants who had
maintained good virologic suppression (HIV-RNA < 50
copies/mL). When the analysis was restricted to include only
this virologically suppressed population and compared the two
treatment groups, the conclusions from the intention to treat
analysis remained unchanged. For all measures of cognition,
the effect sizes for treatment differences remained small in mag-
nitude and none were statistically significant.
Over half (54.7%) of this virologically suppressed (HIV-
RNA < 75 copies/mL) study, population had impaired
neurocognition at baseline. The reason for this increased rate
of cognitive impairment is unclear and may reflect social or
demographic characteristics of the sample itself, or some con-
sequence of involvement in this study. While this classifica-
tion enabled the comparison of the effects of the study treat-
ments, the estimates of cognitive impairment observed in this
study may not be reflective of cognitive impairment in the
general population of HIV-infected, ART-experienced adults.
The rates of impaired neurocognition reported for HIV-
infected adults vary by study, and the rates observed in this
analysis are consistent with some, but not all, studies. For
example, one study enrolled 50 patients with HIV-1 RNA <
50 copies/mL and no self-identified neurocognitive impair-
ment concerns at screening, however subsequent detailed neu-
ropsychological testing with multiple assessments demon-
strated that 32 (64%) had some level of neurocognitive dys-
function (Simioni et al. 2010). Another study in aviremic pa-
tients reported that depending on the assessment method used,
32 to 51% of their study population could be classified as
having neurocognitive impairment (Wintson et al. 2010).
Two additional studies (Cysique et al. 2011; Heaton et al.
2010) reported similar percentages of patients with impaired
neurocognition using detailed neuropsychological testing, of
42% (49/116) and 52% (814/1555), respectively, although in
these studies, not all participants were virologically sup-
pressed (60% and 41%, respectively). Comparatively, lower
rates of neurocognitive impairment (19%; 19/101) have been
observed in an eight test version of the Cogstate battery in
28 J. Neurovirol. (2019) 25:22–31
virologically suppressed patients (HIV-1 RNA < 50
copies/mL); the authors suggested that as the population under
evaluation was a primarily older Caucasian population (medi-
an age 53 years; median time since HIV diagnosis 14 years),
and could represent a Bsurvivor^ subgroup with advanced
clinical presentation (Garvey et al. 2011).
Numerous studies have evaluated whether specific antiretro-
viral drugs or ART regimens, especially in patients with viro-
logic suppression can impact neurocognitive function or what
specific medical or demographic factors may impact
neurocognitive function or the level of HIV-1 RNA in the
CNS, but such studies have yielded mixed results (Arenas-
Pinto et al. 2016; Cusini et al. 2013; Cysique et al. 2004; De
Luca et al. 2002; Ellis et al. 2011; Giancola et al. 2006; Marra
et al. 2009; Munoz-Moreno et al. 2008; Robertson et al. 2004,
2007, 2016; Smurzynski et al. 2011; Winston et al. 2010,
2013). In this ASSURE analysis, neurocognitive performance
within treatment groups (TDF/FTC + ATV/r or ABC/3TC +
ATV) remained stable over the 48 weeks of treatment and there
was no significant difference between treatment groups in
neurocognitive performance over the 48 week treatment peri-
od. While four risk factors at baseline were significantly asso-
ciated with impaired neurocognitive performance on specific
tests or when performance was assessed categorically, after
adjusting for baseline and relevant demographic and medical
covariates, there were no differences in performance between
the ATV +ABC/3TC and ATV/r + TDF/FTC treatment groups
for any of the Cogstate outcomes.
Conclusions
In this aviremic, treatment-experienced population, there were
no neurocognitive differences in the performance between the
ATV + ABC/3TC and ATV/r + TDF/FTC treatment groups;
the baseline-adjusted neurocognitive function remained stable
and equivalent over 48 weeks with both treatment regimens.
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